Interrogation of human microglial phagocytosis by CRISPR genome editing

Jason Cheng-Yu Chang1, Cheng-You Wang1, Steven Lin1,2

  • 1Institute of Biological Chemistry, Academia Sinica, Taipei, Taiwan.

PubMed
Abstract

Insights

We developed a CRISPR genome editing platform for HMC3 cells, enhancing their ability to phagocytose amyloid beta and glioblastoma. This robust method enables precise genetic modification of microglia for functional studies.

Area of Science:

  • Neuroscience
  • Genetics
  • Cell Biology

Background:

  • Microglia, crucial for central nervous system function, are challenging to study due to difficulties in obtaining and culturing primary human cells.
  • The HMC3 cell line offers a more accessible model for human microglia research, but lacks established genetic modification methods.
  • Understanding microglial biology is vital for neurodegenerative diseases and brain cancers.

Purpose of the Study:

  • To establish a robust CRISPR genome editing platform for the HMC3 human microglia cell line.
  • To demonstrate the platform's utility in modifying genes related to amyloid beta and glioblastoma phagocytosis.
  • To enhance the phagocytic capabilities of HMC3 cells for improved disease modeling.

Main Methods:

  • Utilized CRISPR-Cas9 ribonucleoprotein (RNP) electroporation with synthetic DNA repair templates for precise genetic modification of HMC3 cells.
  • Performed gene knockouts (KO) and knock-ins (KI) including epitope tags, synthetic promoters, and fluorescent reporter genes.
  • Assessed editing efficiency via DNA sequencing, immunofluorescence, and flow cytometry, and evaluated phagocytic activity using in vitro assays with amyloid beta and glioblastoma cells.

Main Results:

  • Achieved high-efficiency single (>90%) and double (>70%) gene knockouts with no detectable off-target edits.
  • Successfully inserted a synthetic promoter to upregulate CD14 and TREM2, genes critical for microglial phagocytosis.
  • Demonstrated enhanced phagocytosis of amyloid beta peptides and altered phagocytic characteristics towards apoptotic glioblastoma cells in edited HMC3 lines.

Conclusions:

  • CRISPR-Cas9 RNP electroporation provides a robust and efficient method for genetically modifying HMC3 cells.
  • This platform facilitates functional studies on microglial phagocytosis of amyloid beta and tumor cells.
  • The developed technology is adaptable for investigating diverse aspects of microglial biology.